Eli Lilly

Lilly's Donanemab gets CDSCO approval for early Alzheimer's treatment

Eli Lilly has secured CDSCO marketing authorisation for donanemab, an amyloid-targeting therapy for adults with early symptomatic Alzheimer's

Lilly's investment reflects long-term commitment to India: Winselow Tucker

Eli Lilly invests $1B in India as Mounjaro succeeds, Hyderabad site to boost global supply and innovation

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets

Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug

Eli Lilly's weight-loss injection Mounjaro saw a 42% jump in September sales, touching Rs 80 crore as more patients shift to higher doses amid rising demand

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Eli Lilly to invest over $1 billion in India to boost manufacturing

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

'Worst in Europe': Eli Lilly CEO slams UK drug prices, warns of fewer drugs

Eli Lilly CEO Dave Ricks slammed the UK's strict drug pricing rules, warning that the country risks losing new medicines and investment unless changes are made to its rebate scheme

After Mounjaro success, Eli Lilly plans to launch weight-loss pill in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

Ozempic maker Novo Nordisk to cut 9,000 job to save $1.3 billion annually

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Demand for obesity drugs soars in India as Lilly, Novo jostle for mkt share

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

The company plans to submit efsitora, its once-weekly insulin for type 2 diabetes, to global regulators by end-2026 following positive Phase 3 trial outcomes